TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9014620

Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms kg-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neostigmine 20 micrograms kg-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neostigmine 10 micrograms kg-1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neostigmine (various doses)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neostigmine (doses > 20 micrograms kg-1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Neostigmine 50 micrograms kg-1 or more
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg-1
Number of subjects: 90
Study: 1312888

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3926591

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms b.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg b.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms h.s.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms h.s.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31032782

Group type: EXPERIMENTAL
Intervention: Memory rehabilitation (10 weekly sessions of a manualised memory rehabilitation programme)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Memory rehabilitation
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study: 29418016

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.67 mg/m2/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment with Sex Steroid Replacement Therapy (SSRT)
Number of subjects: 27
Study: 26817525

Group type: EXPERIMENTAL
Intervention: Oral tramadol 50 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 25455115

Group type: EXPERIMENTAL
Intervention: Implementation intentions-based intervention
Number of subjects: 470

Group type: COMPARATOR
Intervention: Comparison group (generic health information on diet and exercise)
Number of subjects: 470
Study: 22329446

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard therapy (physical therapy, topical dimethyl sulfoxide, analgesics, transcutaneous stimulation, sympathetic blockade)
Number of subjects: 74
Study: 20192532

Group type: EXPERIMENTAL
Intervention: Modifier-noun combinations with varying semantic categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head noun with compatible semantic category of the modifier
Number of subjects: 0
Study: 17602007

Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 38
Study: 15744348

Group type: EXPERIMENTAL
Intervention: Intravenous 6-mercaptopurine (1 g/m(2))
Number of subjects: 877

Group type: COMPARATOR
Intervention: No intravenous 6-mercaptopurine (Control Group, Arm A)
Number of subjects: 877
Study: 12173072

Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg once a day for two days prior to HA and during initial three days at HA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9458539

Group type: EXPERIMENTAL
Intervention: Granisetron (GRA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Granisetron plus prednisolone (GRA + PRE)
Number of subjects: 90
Study: 7889578

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 2218831

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ampicillin plus tobramycin
Number of subjects: 96
Study: 91437

Group type: EXPERIMENTAL
Intervention: High dose cis-platinum (1-hour infusion with mannitol diuresis)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low dose cis-platinum (8-hour infusion without diuresis)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Three-drug program (vinblastine, actinomycin D, and cis-platinum)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cyclic crossover regimen (three regimens each containing three drugs)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Limited-disease patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Advanced-disease patients
Number of subjects: 45
Study: 30854443

Group type: EXPERIMENTAL
Intervention: DCE-MRI before radiation therapy (pre-RT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DCE-MRI after 2 weeks of radiation therapy (2wkRT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DCE-MRI assessment
Number of subjects: 62
Study: 27657674

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg) plus best supportive care
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 643
Study: 25461393

Group type: EXPERIMENTAL
Intervention: alendronate 70mg weekly
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: zoledronate (10(‐9)‐10(‐6)M)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: alendronate (10(‐7) and 10(‐6))
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: zoledronate (10(‐10)‐10(‐6)M)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: calcitriol (10(‐8)M)
Number of subjects: 18
Study: 22991162

Group type: EXPERIMENTAL
Intervention: Expressive Writing Intervention (EWI) - emotional disclosure
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group - non-emotional topic
Number of subjects: 507
Study: 21427113

Group type: EXPERIMENTAL
Intervention: eGFR <45
Number of subjects: 2967
Study: 20128296

Group type: EXPERIMENTAL
Intervention: Needle‐pricking bleeding combined with pulling‐rotating manipulation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Simple pulling‐rotating manipulation (Control)
Number of subjects: 198
Study: 17095896

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 27
Study: 15536656

Group type: EXPERIMENTAL
Intervention: New parameter for measuring sagging amplitude of submental skin
Number of subjects: 66
Study: 10772372

Group type: EXPERIMENTAL
Intervention: Personalized follow-up (weekly telephone contact for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no personalized follow-up)
Number of subjects: 30
Study: 9001919

Group type: EXPERIMENTAL
Intervention: Environmental tobacco smoke (ETS) exposure (20 ppm CO) for 3 hours (7:00 to 10:00 p.m.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ambient air (sham) exposure for 3 hours (7:00 to 10:00 p.m.)
Number of subjects: 17
Study: 8877210

Group type: EXPERIMENTAL
Intervention: Lens tube
Number of subjects: 72

Group type: COMPARATOR
Intervention: Donaldson tube
Number of subjects: 72
Study: 3537249

Group type: EXPERIMENTAL
Intervention: Methionyl human growth hormone (0.125 mg/kg three times per week)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Oxandrolone (0.125 mg/kg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination therapy (hGH plus oxandrolone)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 70
Study: 31195408

Group type: EXPERIMENTAL
Intervention: Genetically predicted BMI
Number of subjects: 367703

Group type: EXPERIMENTAL
Intervention: Genetically predicted fat mass index
Number of subjects: 367703

Group type: EXPERIMENTAL
Intervention: Genetically predicted fat-free mass index
Number of subjects: 367703
Study: 31467392

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28222552

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP) approach
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 43
Study: 25938886

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (50,000 IU every 2 weeks from 20 to 32 weeks of gestation)
Number of subjects: 60
Study: 23761202

Group type: EXPERIMENTAL
Intervention: Liveonline aftercare program (6 units comprehensive multimodal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liveonline aftercare program
Number of subjects: 0
Study: 21601839

Group type: EXPERIMENTAL
Intervention: Judgments based on the agent's innocent intent regarding accidental harms.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judgments based on the agent's guilty intent regarding failed attempts to harm.
Number of subjects: 0
Study: 19139333

Group type: EXPERIMENTAL
Intervention: Atropine plus plano lens
Number of subjects: 180

Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 180
Study: 17003082

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg every other day
Number of subjects: 80
Study: 15041559

Group type: EXPERIMENTAL
Intervention: Partial splenic embolization with gelatin sponge particles (60%-80% embolized volume)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Partial splenic embolization with gelatin sponge particles (40%-60% embolized volume)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Partial splenic embolization (both groups)
Number of subjects: 45
Study: 11357028

Group type: EXPERIMENTAL
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 50
Study: 9206959

Group type: EXPERIMENTAL
Intervention: Stomach ulcer
Number of subjects: 71

Group type: COMPARATOR
Intervention: Duodenal ulcer
Number of subjects: 71
Study: 8196788

Group type: EXPERIMENTAL
Intervention: Preoperative instruction and physical therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: No preoperative instruction and physical therapy
Number of subjects: 64
Study: 3359548

Group type: EXPERIMENTAL
Intervention: Low-residue diet with an additional intake of 1200 Kcal and 32 g protein daily (Group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uninterrupted colonic preparation with dietary restrictions for 4-8 days (450 calories; 25 g proteins daily) (Group A)
Number of subjects: 24
Study: 29952297

Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 463
Study: 28150971

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 26187378

Group type: EXPERIMENTAL
Intervention: Optimised patient information materials
Number of subjects: 2035

Group type: COMPARATOR
Intervention: Standard patient information materials
Number of subjects: 2035
Study: 22890567

Group type: EXPERIMENTAL
Intervention: Bone graft (BG) from the iliac crest
Number of subjects: 107

Group type: COMPARATOR
Intervention: No bone graft (NBG)
Number of subjects: 107
Study: 20925067

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg bid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg bid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg tid
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 19503030

Group type: EXPERIMENTAL
Intervention: Needle structure scintillator with 40% reduction of exposure
Number of subjects: 296

Group type: COMPARATOR
Intervention: Granular structure scintillator
Number of subjects: 296
Study: 16740918

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Thrombolytic treatment (TT)
Number of subjects: 1319
Study: 15541014

Group type: EXPERIMENTAL
Intervention: Atipamezole (three-step infusion aiming for serum concentrations of 10, 30, and 90 ng ml(‐1))
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atipamezole (three-step infusion)
Number of subjects: 6
Study: 11555222

Group type: EXPERIMENTAL
Intervention: Computer-based teaching package
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both groups (Computer-based and Lecture)
Number of subjects: 166
Study: 9433582

Group type: EXPERIMENTAL
Intervention: Ascertainment scheme with exactly two affected sibs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascertainment scheme with two sibs who had extremely discordant values for Q1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ascertainment scheme with sib pairs extremely discordant for Q2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random ascertainment scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Affected sib pairs or sib pairs with extremely discordant values for Q1
Number of subjects: 0
Study: 8491246

Group type: EXPERIMENTAL
Intervention: Nitecapone 100 mg t.d.s. for 7 days
Number of subjects: 15
Study: 3555605

Group type: EXPERIMENTAL
Intervention: 0.25% idoxuridine ointment applied twice daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo ointment applied twice daily for 2 weeks
Number of subjects: 24
Study: 30032937

Group type: COMPARATOR
Intervention: Individually-based treatment (IBT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy plus individually-based treatment (BCT + IBT)
Number of subjects: 61
Study: 27311248

Group type: EXPERIMENTAL
Intervention: Dulaglutide (subcutaneous 0.75 or 1.5 mg once weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin, sitagliptin, exenatide, insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 0
Study: 25333428

Group type: EXPERIMENTAL
Intervention: Dental care provided by a dental surgeon, 4‐5 times a week, including routine oral hygiene, teeth brushing, tongue scraping, removal of calculus, atraumatic restorative treatment of caries, and tooth extraction
Number of subjects: 254

Group type: COMPARATOR
Intervention: Routine oral hygiene only, including the use of chlorhexidine as a mouth rinse, performed by ICU nurse staff
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Dental care provided by a dental surgeon
Number of subjects: 254

Group type: COMPARATOR
Intervention: Routine oral hygiene only
Number of subjects: 254
Study: 23373662

Group type: EXPERIMENTAL
Intervention: Discontinuation of opportunistic infections prophylaxis
Number of subjects: 74

Group type: COMPARATOR
Intervention: Continuation of opportunistic infections prophylaxis
Number of subjects: 74
Study: 20952013

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100 U or greater
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 313

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 313
Study: 18662285

Group type: EXPERIMENTAL
Intervention: 15 mg oxazepam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 8
Study: 21321086

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg once daily (qd)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Motesanib 75 mg twice daily (b.i.d.) 5 days on/2 days off
Number of subjects: 186

Group type: COMPARATOR
Intervention: Bevacizumab 15 mg/kg every 3 weeks (q3w)
Number of subjects: 186
Study: 15933353

Group type: EXPERIMENTAL
Intervention: Co-prescription of heroin (inhalable or injectable) over 12 months
Number of subjects: 430

Group type: COMPARATOR
Intervention: Methadone alone (maximum 150 mg a day)
Number of subjects: 430
Study: 12131942

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac, 75 mg associated with intravenous physiological saline, 10 ml
Number of subjects: 120

Group type: COMPARATOR
Intervention: Physiological saline alone (placebo)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 120
Study: 9796841

Group type: EXPERIMENTAL
Intervention: Perindopril (ACE inhibitor)
Number of subjects: 10500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10500
Study: 7639004

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 68
Study: 2468183

Group type: EXPERIMENTAL
Intervention: Single-agent ifosfamide
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: BIP combination (ifosfamide, cisplatin, and bleomycin)
Number of subjects: 98
Study: 871634

Group type: EXPERIMENTAL
Intervention: 2 mg prazosin with 100 mmol sodium intake
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.5 mg prazosin with 100 mmol sodium intake
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 2 mg prazosin with 250 mmol sodium intake
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 0.5 mg prazosin with 250 mmol sodium intake
Number of subjects: 7

Group type: COMPARATOR
Intervention: High sodium intake (250 mmol)
Number of subjects: 7
Study: 11425770

Group type: EXPERIMENTAL
Intervention: Warfarin alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Combination therapy (Aspirin and Warfarin)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (Placebo + Warfarin)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (Placebo + Aspirin)
Number of subjects: 135
Study: 30664736

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) plus walking
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (usual diet and exercise)
Number of subjects: 42
Study: 30021096

Group type: EXPERIMENTAL
Intervention: l-glutamine (0.3 g/kg per dose, administered twice daily)
Number of subjects: 230

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 230
Study: 26718379

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (940-nm gallium-aluminum-arsenic diode laser, 200 mW, 20 seconds at 3 points on buccal mucosa)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo laser therapy (laser not turned on)
Number of subjects: 88
Study: 25290091

Group type: EXPERIMENTAL
Intervention: dalotuzumab/MK‐2206
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: dalotuzumab/MK‐0752
Number of subjects: 47
Study: 22581038

Group type: EXPERIMENTAL
Intervention: Glucosafe decision support system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Patient-specific carbohydrate absorption factor
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BG-dependent variable insulin appearance rate
Number of subjects: 12
Study: 20350695

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiVP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Right ventricular pacing (RVP)
Number of subjects: 60
Study: 17275636

Group type: EXPERIMENTAL
Intervention: Warfarin dosing by nomogram
Number of subjects: 216

Group type: COMPARATOR
Intervention: Warfarin dosing by house staff
Number of subjects: 216
Study: 16206365

Group type: EXPERIMENTAL
Intervention: Patient self-report instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigator instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current methods of adverse event reporting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrument development
Number of subjects: 0
Study: 12851279

Group type: EXPERIMENTAL
Intervention: Tifacogin (0.025 mg/kg per hour for 96 hours, n = 880)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Placebo (arginine citrate buffer, n = 874)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Tifacogin (n = 722)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Placebo (n = 722)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Tifacogin (low INR, n = 83)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Placebo (low INR, n = 118)
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Tifacogin
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1754

Group type: EXPERIMENTAL
Intervention: Tifacogin (low INR)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Placebo (low INR)
Number of subjects: 1754
Study: 10536644

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion at incremental doses from 0.010 to 0.030 microgram kg‐1 min‐1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 36
Study: 8902992

Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction
Number of subjects: 38

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study: 1867449

Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding for greater than 4 months
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Cow milk whey hydrolysate formula (NAN/HA)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conventional cow milk formula (Similac)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Soy-based formula (Isomil)
Number of subjects: 288
Study: 7034840

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metrizoate
Number of subjects: 20
Study: 31483544

Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30137664

Group type: EXPERIMENTAL
Intervention: Concizumab (0.25, 0.5, and 0.8 mg kg‐1, once every 4 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Concizumab (highest dose cohort)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27904632

Group type: EXPERIMENTAL
Intervention: Reflexology (3 sessions of 40 minutes each for 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 24467549

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 512

Group type: COMPARATOR
Intervention: Allopurinol 300 mg
Number of subjects: 512
Study: 23148736

Group type: EXPERIMENTAL
Intervention: Doripenem (7-day course, 1g as a four-hour infusion every eight hours)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (10-day course, 1g as a one-hour infusion every eight hours)
Number of subjects: 274
Study: 21051181

Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block with nerve stimulator
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Spielberger test for anxiety assessment
Number of subjects: 184